ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2022
Genetic Aberrations and Interaction of NEK2 and TP53 Accelerate Aggressiveness of Multiple Myeloma.
Open access · goldAbstract read
In one paragraph
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 29 citations in OpenAlex.
- Knockdown of caspase-activated DNase and B-cell lymphoma 2 inhibits cell proliferation and drug resistance in TP53-mutant multiple myeloma.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Zinc finger protein 695 facilitates the proliferation of colorectal cancer cells through activation of the NEK2 and PI3K/Akt/mTOR signaling pathways.Oncology reports · 2025Article
- Enhancer Extrachromosomal Circular DNA ANKRD28 Elicits Drug Resistance via POU2F2-Mediated Transcriptional Network in Multiple Myeloma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- NEK2 promotes the progression of osteosarcoma through the AKT/p-AKT pathway and interacts with FoxM1.Medical oncology (Northwood, London, England) · 2025Article
- Genomic characteristics and prognostic correlations in Chinese multiple myeloma patients.BMC medical genomics · 2025Article
- Role of NEK2 in tumorigenesis and tumor progression.Trends in molecular medicine · 2025Review
- Leveraging a disulfidptosis-based signature to characterize heterogeneity and optimize treatment in multiple myeloma.Frontiers in immunology · 2025Article
- NEK2 inhibition alleviates lipopolysaccharide-induced endothelial injury.ASPET discovery · 2025Article
- KLF5 promotes the ossification process of ligamentum flavum by transcriptionally activating CX43.Journal of orthopaedic surgery and research · 2024Article
- Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care.Cancers · 2024Article
- Mechanisms of the role of proto-oncogene activation in promoting malignant transformation of mature B cells.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024Article
- Transcriptome and Weighted Gene Co-Expression Network Analysis for Feather Follicle Density in a Chinese Indigenous Breed.Animals : an open access journal from MDPI · 2024Article
- Evolutionary dynamics and functional characterization of proximal duplicated sorbitol-6-phosphate dehydrogenase genes in Rosaceae.Frontiers in plant science · 2024Article
- Differential Expression of NEK Kinase Family Members in Esophageal Adenocarcinoma and Barrett's Esophagus.Cancers · 2023Article
- High expression of VARS promotes the growth of multiple myeloma cells by causing imbalance in valine metabolism.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023Article
- NEK2 promotes esophageal squamous cell carcinoma cell proliferation, migration and invasion through the Wnt/β-catenin signaling pathway.Discover oncology · 2023Article
- [Latest Findings on the Mechanism of the Interaction Between Multiple Myeloma Cells and Bone Marrow Microenvironment].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2023Review
- Network pharmacology- and molecular docking-based investigation of the therapeutic potential and mechanism of daucosterol against multiple myeloma.Translational cancer research · 2023Article
- Article
- IntestinalCancers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 3 institutions in 3 countries.
Xiangling FengState Key Laboratory of Experimental Hematology, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Key Laboratory of Carcinogenesis, National Health and Family Planning Commission; Department of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, 410028, China.
Jiaojiao GuoState Key Laboratory of Experimental Hematology, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Key Laboratory of Carcinogenesis, National Health and Family Planning Commission; Department of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, 410028, China.
Gang AnState Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, 300041, China.
Yangbowen WuXiang Ya School of Public Health, Central South University, Changsha, Hunan, 410028, China.
Zhenhao LiuState Key Laboratory of Experimental Hematology, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Key Laboratory of Carcinogenesis, National Health and Family Planning Commission; Department of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, 410028, China.
Bin MengState Key Laboratory of Experimental Hematology, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Key Laboratory of Carcinogenesis, National Health and Family Planning Commission; Department of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, 410028, China.
Nihan HeState Key Laboratory of Experimental Hematology, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Key Laboratory of Carcinogenesis, National Health and Family Planning Commission; Department of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, 410028, China.
Xinying ZhaoXiang Ya School of Public Health, Central South University, Changsha, Hunan, 410028, China.
Shilian ChenState Key Laboratory of Experimental Hematology, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Key Laboratory of Carcinogenesis, National Health and Family Planning Commission; Department of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, 410028, China.
Yinghong ZhuState Key Laboratory of Experimental Hematology, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Key Laboratory of Carcinogenesis, National Health and Family Planning Commission; Department of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, 410028, China.
Jiliang XiaState Key Laboratory of Experimental Hematology, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Key Laboratory of Carcinogenesis, National Health and Family Planning Commission; Department of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, 410028, China.
Xin LiThe third Xiangya Hospital of Central South University, Changsha, Hunan, 410013, China.
Zhiyong YuDepartment of Pathology, Changsha eighth hospital, Changsha, Hunan, 410199, China.
Ruixuan LiThe third Xiangya Hospital of Central South University, Changsha, Hunan, 410013, China.
Guofeng RenXiang Ya School of Public Health, Central South University, Changsha, Hunan, 410028, China.
Jihua ChenXiang Ya School of Public Health, Central South University, Changsha, Hunan, 410028, China.
Minghua WuState Key Laboratory of Experimental Hematology, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Key Laboratory of Carcinogenesis, National Health and Family Planning Commission; Department of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, 410028, China.
Yanjuan HeState Key Laboratory of Experimental Hematology, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Key Laboratory of Carcinogenesis, National Health and Family Planning Commission; Department of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, 410028, China.
Lugui QiuState Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, 300041, China.
Jiaxi ZhouState Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, 300041, China.
Wen ZhouState Key Laboratory of Experimental Hematology, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Key Laboratory of Carcinogenesis, National Health and Family Planning Commission; Department of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, 410028, China.ORCID 0000-0003-4085-7714
Central South University · CNInstitute of Hematology & Blood Diseases Hospital · CNThe Eighth Hospital of Xi'an · CN
Funding
Fundamental Research Fund for Graduate of Central South University 2019zzts087Ministry of Science and Technology of China 2018YFA0107800National Natural Science Foundation of China 81630007National Natural Science Foundation of China 81974010National Natural Science Foundation of China 82130006Natural Science Foundation of Hunan Province 2020WK2006Natural Science Foundation of Hunan Province 2021JJ3089SKLEH-Pilot Research Grant ZK16-04SKLEH-Pilot Research Grant ZK21-05Strategic Priority Research Program of Central South University ZLXD2017004
Abstract
It has been previously shown that (never in mitosis gene A)-related kinase 2 (NEK2) is upregulated in multiple myeloma (MM) and contributes to drug resistance. However, the mechanisms behind this upregulation remain poorly understood. In this study, it is found that amplification of NEK2 and hypermethylation of distal CpG islands in its promoter correlate strongly with increased NEK2 expression. Patients with NEK2 amplification have a poor rate of survival and often exhibit TP53 deletion, which is an independent prognostic factor in MM. This combination of TP53 knockout and NEK2 overexpression induces asymmetric mitosis, proliferation, drug resistance, and tumorigenic behaviors in MM in vitro and in vivo. In contrast, delivery of wild type p53 and suppression of NEK2 in TP53
Indexed as
Multiple MyelomaBortezomibCell Line, TumorHumansNIMA-Related KinasesTumor Suppressor Protein p53BortezomibNEK2 protein, humanNIMA-Related KinasesTP53 protein, humanTumor Suppressor Protein p53amplificationmultiple myelomaNEK2TP53transcriptional regulation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.